Nuclear factor NF-kappa-B p105 subunit (p50) (NF-κB p50)

The Nuclear factor NF-kappa-B p105 subunit (NFKB1), which is processed into the active p50 subunit, is a pivotal transcription factor involved in the regulation of genes associated with immunity, inflammation, and cell survival [1, 2]. As a member of the Rel family, p50 typically forms heterodimers with p65 (RelA) to activate the transcription of pro-inflammatory cytokines and anti-apoptotic factors [3]. In its homodimeric form, p50 can also act as a transcriptional repressor, providing a complex regulatory mechanism for gene expression [3, 4]. Dysregulation of the p50 subunit is strongly implicated in the pathogenesis of chronic inflammatory conditions, autoimmune diseases, and various malignancies, where it often facilitates tumor cell evasion of apoptosis [4, 5]. Pharmacological targeting of this pathway includes the use of proteasome inhibitors like bortezomib, which prevents the generation of p50 from its p105 precursor, and various anti-inflammatory agents that inhibit the upstream activation of the NF-κB signaling cascade [5, 15]. Additionally, small molecules and biological agents are being explored to specifically disrupt p50 DNA binding or its dimerization with other Rel proteins [6, 7]. Because of its ubiquitous expression and fundamental role in host defense, therapeutic modulation of p50 requires careful consideration of systemic side effects [12, 13]. Monitoring p50 nuclear localization and DNA-binding activity serves as a critical biomarker for assessing pathway activation in clinical settings [9, 10].

Other names

NFKB1p105p50Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1KBF1EBP-1

Inhibition of proteasomal processing of p105 to p50, inhibition of IκB degradation, prevention of nuclear translocation, and interference with DNA binding.